Skip to main content

Skyrizi (Risankizumab-Rzaa) & Signal Identification

Basic Details
Status
Ongoing
Last Updated
Thursday, November 7, 2024
Original Posting Date
Health Outcome(s)
signal identification
Purpose
Signal Identification
Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
No
Analytic Code Link(s) (2)
Outcome Monitoring Following Risankizumab Use: A Signal Identification Analysis Outcome Monitoring Following Risankizumab Use: A Supplemental Signal Identification Analysis
Result(s) (3)
Outcome Monitoring Following Risankizumab Use: A Signal Identification Analysis Outcome Monitoring Following Risankizumab Use: A Supplemental Signal Identification Analysis Utilization of Risankizumab and Comparator Products: A Descriptive Analysis
Related Publication(s) and/or Presentation(s) (1)
Presentation: Safety Signal Identification for Risankizumab-rzaa in the Sentinel Distributed Database Using Self-Controlled and Active Comparator Study Designs